PCR testing in blood and lung washings to monitor invasive pulmonary aspergillosis
Official title: PCR for Aspergillus Fumigatus in Blood and Bronchoalveolar Lavage Fluid for Monitoring Cases of Invasive Aspergillosis: What is Its Prognostic Value
Run by University Hospital, Strasbourg, France · NCT07313527 · Data updated 2026-11-12
This will test whether repeated PCR tests for Aspergillus fumigatus in blood and bronchoalveolar lavage fluid can track treatment response in adults with invasive pulmonary aspergillosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Locations | 1 site (Strasbourg) |
| Status | Recruiting |
| Started | March 17, 2025 |
| Main results expected | February 2026 |
| Study ends | February 2026 |
| Registry record updated | January 2, 2026 |
| Trial ID | NCT07313527 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18) with a probable or proven diagnosis of invasive pulmonary aspergillosis who had a positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage at CHU Strasbourg between 2017 and 2024.
✕Probably not a fit
Patients who received effective antifungal therapy before their first PCR, lacked subsequent PCR testing, had non-fumigatus Aspergillus infections, or died within 72 hours of starting treatment are unlikely to benefit from the study findings.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational retrospective cohort includes adults with probable or proven invasive pulmonary aspergillosis who had a positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage performed at Strasbourg University Hospital between January 1, 2017 and December 31, 2024. Investigators will chart changes in PCR results over the course of antifungal therapy and correlate PCR positivity and quantitative trends with clinical outcomes, serum galactomannan, and survival. Patients who lacked follow-up PCRs, received effective antifungal treatment before the first PCR, or died within 72 hours of treatment start are excluded. No experimental interventions are given; the study analyzes existing clinical and laboratory data from routine care.
Why it matters
Potential benefit: If successful, clinicians might use PCR trends to tell whether antifungal treatment is working and adjust care sooner.
How similar studies have gone: Some prior work has combined Aspergillus PCR with galactomannan to support diagnosis and monitoring, but few studies have followed PCR level changes during treatment and the prognostic value remains limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients aged 18 years or older * Positive Aspergillus fumigatus PCR on serum or bronchoalveolar lavage fluid at diagnosis, performed at the Strasbourg University Hospital between January 1, 2017, and December 31, 2024. Exclusion Criteria: * No subsequent Aspergillus fumigatus PCR (\>24h) * No diagnosis of probable or proven invasive aspergillosis (EORTC/MSGERC 2020 criteria) * Effective antifungal treatment against Aspergillus initiated before the first PCR * Death \<72h after starting antifungal treatment
Where it's running
-
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France Recruiting
Study contacts
- Study coordinator: baptiste Hoellinger, MD
- Email: baptiste.hoellinger@chru-strasbourg.fr
- Phone: 33 3 69 55 05 45
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Breath analysis to detect fungal infections in leukemia patients
This study is testing if analyzing breath samples can help doctors detect fungal infections in leukemia patients who are at high risk due to their treatment.
-
Early diagnosis of invasive lung aspergillosis
This study is trying to see if new tests can help doctors diagnose lung infections caused by fungus earlier in critically ill patients.
-
Investigating the link between influenza and invasive pulmonary aspergillosis
This study looks at how having the flu affects patients with severe pneumonia in the ICU and whether it leads to more serious lung infections.
-
Non-invasive diagnosis of lung infections caused by mold in children
This study is testing a new, non-invasive way to find lung infections caused by mold in children who are at high risk due to serious health conditions.
-
FUNGAL-P: A score to spot fungal pneumonia early in adults with pneumonia
Aimed at adults with pneumonia, this study tests a new score to help identify fungal pneumonia sooner so doctors can test appropriately and start antifungal treatment when needed.
-
Detecting azole resistance in invasive aspergillosis patients using blood samples
This study is testing a new way to quickly find out if patients with a serious fungal infection have a type that is resistant to common treatments, using blood samples from people with weakened immune systems.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.